

PREFERRED DENTAL TECHNOLOGIES INC.

Press Release

B01- 185 Provencher Blvd
Winnipeg, MB R2H 0G4
Tel: 204.691.3722
Email: info@prefdent.com

Date: October 31, 2018

**CSE- PDTI
US OTC: PDTTF**

Preferred Dental Technologies Inc. (“Company”) (CSE: PDTI, US OTC: PDTTF): Announces “PDT Wellness” initiative and the introduction of new organic, pharmaceutical grade CBD products for dental offices

Preferred Dental Technologies Inc. (PDTI), through its wholly owned subsidiary Preferred Dental Implant Corp. (PDIC), is pleased to announce the introduction of “PDT Wellness”, a line of products designed for dental offices and beyond; dedicated to innovative health care for the patient. This new venture consists of launching a series of products composed of highest quality, organic, pharmaceutical grade cannabidiol (CBD) grown, harvested and manufactured in the US. CBD is one of the non-intoxicating components of hemp, and one that has indicated significant supplemental medical benefits. All “PDT Wellness” products are THC free and will be marketed where permitted following individual state and federal regulations.

The growing body of research surrounding the effectiveness of CBD assisting in providing some relief of pain and anxiety is incredibly promising. With this in mind, PDTI as part of its mission statement of providing innovative solutions in the dental market has been keeping an eye on this developing field for some time. We are pleased to announce today the culmination of this project. PDIC has negotiated a turn-key supply operation including fulfilment center capable of delivering the highest quality pharmaceutical grade CBD to the dental market. Initial product suite includes soft gel capsules and sublingual tincture delivery methods in a variety of dosage concentrations and we expect other products to follow as we continue to grow.

The current opioid epidemic that has rocked the healthcare industry has brought further attention to the potential of CBD supplements, deemed as a safe alternative method to consider when addressing pain and other patient symptoms. This is particularly true in the dental space, where according to many estimates, dentists prescribe 12% of all immediate release opioids in the US (including 50% of all opioids prescribed to adolescents), second only to family physicians (15%) according to FDA numbers. They are also one of the professional groups least likely to provide long term patient follow-up on these prescriptions. Because of this, the American Dental Association has stated that, “dentists play a key role in addressing the opioid crisis” and this past summer, has been crafting new policy to better address this issue. The availability of CBD as a treatment option in other health care sectors has already begun to show signs of reducing the effects and use of opioids.

With the increasing interest in CBD as a supplement and alternative treatment method, questions of product quality are a major concern for health care providers and these legitimate concerns are likely to increase. Health care professionals may feel hesitant to provide CBD options to patients because of unknown quality and source of supply. For this reason, PDIC through its “PDT Wellness” line is proud to announce that every case of our product will contain a full lab report of the product contained within. All “PDT Wellness” products are:

- High quality, pharmaceutical grade CBD
- Organically grown in the US
- THC-Free
- Full spectrum (containing a range of accepted cannabinoids such as CBDa, CBG and terpenes for superior effect)
- Nano emulsion technology creates smaller particles for greater bioavailability and absorption
- Free of contaminants such as pesticides and heavy metals

This will provide “PDT Wellness” products with a longevity most competitors lack. While others chase trends, PDIC aims to provide solutions requested by healthcare professionals, through individual consultation and surveys of concerns, wants and needs.

We have been developing our sales team over the past several months and we anticipate we will have further updates shortly specifically addressing progress made. In addition to the EAS Series dental implant components, our sales representatives are excited to begin introducing CBD based products to dentists and oral surgeons for their consideration. We are expecting product to be available within three weeks’ time.

PDTI President, Mr. Erik Siegmund stated, “Obviously we are incredibly excited to bring news of this development to our shareholders. Regardless of the skill of the dental professional, in the public eye a visit to the dentist is associated with stress and pain. The growing research literature on CBD supplements as an available option to consider in addressing these symptoms provides an alternative for precisely these areas making it a natural fit. Additionally, the data on anti-inflammatory qualities of CBD to date is impressive suggesting a strong role in post treatment healing. PDTI was founded on bringing innovative and practical solutions to the dental industry. Our original EAS Series of dental implant components, our branching into digital 3D print solutions and now the “PDT Wellness” line of CBD products all embody this spirit, one which we plan to continue to grow as the company does. I would like to give thanks to the efforts of our Advisors, Board members and all resource personnel we have engaged with, for spearheading this initiative.”

About PDTI

Preferred Dental technologies Inc. (PDTI) has been established to advance development and commercialization of various evolutionary and disruptive technologies in the dental implant industry.

MISSION – INNOVATIVE & PRACTICAL SOLUTIONS FOR THE DENTAL INDUSTRY

Visit: www.preferredentalimplant.com

www.prefdent.com

On behalf of Preferred Dental Technologies Inc.

Erik Siegmund

Chief Executive Officer

Email: info@prefdent.com

Tel: 204.691.3722

www.prefdent.com

This news release may contain forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the Company's objectives, goals or future plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, those risks set out in the Company's public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither The Canadian Securities Exchange nor its Regulations Services Provider (as that term is defined in the policies of The Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.